Viking Therapeutics, Inc. (LON: 0VQA)

Viking Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	42.81	37.02	16.12	10.7	10.73	9.13
Research & Development	91.16	63.81	54.23	44.98	31.93	23.56
Operating Expenses	133.97	100.83	70.36	55.68	42.66	32.69
Operating Income	-133.97	-100.83	-70.36	-55.68	-42.66	-32.69
Interest Expense	-0.1	-0.09	-0.06	-0.02	-0.11	-0.15
Interest & Investment Income	34.8	15.02	1.59	0.7	3.23	7.05
Currency Exchange Gain (Loss)	-	-	-	0.01	-	-
EBT Excluding Unusual Items	-99.26	-85.9	-68.83	-54.99	-39.54	-25.78
Gain (Loss) on Sale of Investments	0.11	-	-0.04	-	0.04	0
Pretax Income	-99.15	-85.9	-68.87	-54.99	-39.5	-25.78
Net Income	-99.15	-85.9	-68.87	-54.99	-39.5	-25.78
Net Income to Common	-99.15	-85.9	-68.87	-54.99	-39.5	-25.78
Shares Outstanding (Basic)	106	94	77	77	73	72
Shares Outstanding (Diluted)	106	94	77	77	73	72
Shares Change (YoY)	19.97%	22.79%	-0.47%	6.34%	0.89%	24.97%
EPS (Basic)	-0.93	-0.91	-0.90	-0.71	-0.54	-0.36
EPS (Diluted)	-0.93	-0.91	-0.90	-0.71	-0.54	-0.36
Free Cash Flow	-74.25	-73.38	-48.4	-47.59	-21.78	-24.75
Free Cash Flow Per Share	-0.70	-0.78	-0.63	-0.62	-0.30	-0.34
EBIT	-133.97	-100.83	-70.36	-55.68	-42.66	-32.69

Source: S&P Capital IQ. Standard template. Financial Sources.